# Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study

> **NCT04334993** · PHASE2 · UNKNOWN · sponsor: **Israeli Medical Association** · enrollment: 110 (estimated)

## Conditions studied

- Philadelphia-Negative ALL
- High-Risk Cancer

## Interventions

- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT04334993
- **Lead sponsor:** Israeli Medical Association
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-05-01
- **Final completion:** 2025-05-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2021-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04334993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04334993, "Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04334993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*